azetukalner Updated Nov 5
The next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.
- The Phase 3 X-TOLE2 trial delivered strong results: 53.2% median seizure reduction at 25mg vs 10.4% for placebo (p<0.0001), one of the largest placebo-adjusted efficacy signals seen in recent epilepsy trials.
- The NDA for focal seizures was submitted to the FDA on September 17, 2026, backed by over 1,500 patient-years of epilepsy safety data across two positive trials.
- Analyst consensus is Strong Buy (11 Strong Buy, 12 Buy, 2 Hold) with a mean price target of $71.75, implying 83% upside from the current $39.19 price.
- The psychiatry program (MDD and bipolar depression) was paused in September 2026 after neuropsychiatric adverse events including psychosis were observed, which wiped 30% off the stock in a single day and casts a shadow over the broader azetukalner safety profile.
- Deutsche Bank downgraded the stock from Buy to Hold on Sept 18, 2026, and several large institutional holders trimmed or exited in Q2 2026, including Wellington Management (trimmed 70.5%), Holocene Advisors (exited), and Jennison Associates (near-exit, trimmed 84.2%).
- Elevated short-sale volume (z-score 1.51 vs the stock's own history) suggests bearish positioning around the stock.